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Abstract
Purpura fulminans (PF) is an ominous cutaneous condition usually associated with
meningococcemia. PF in the newborn is rarely reported. We report the case of a female preterm
infant with extensive PF due to group B streptococcus (GBS) septicemia. She developed multi-
organ system failure despite neonatal intensive care support and succumbed 9 days later. GBS,
sensitive to penicillin, was isolated from the blood cultures of the mother and the infant. Invasive
early GBS infection is common in the newborn and is empirically treated with prompt institution
of intravenous antibiotics. PF associated with GBS is a rare cutaneous sign that must not be missed.
Mortality remains high despite aggressive treatment and ICU support.
Introduction
Purpura fulminans (PF) is an ominous cutaneous condi-
tion usually associated with meningococcemia [1-9]. PF
in the newborn is rarely reported [6-12] We report the case
of a female preterm infant with extensive PF due to group
B streptococcus (GBS) septicemia and discussion issues of
management of this rare but often fatal condition.
Case
Purupura fulminans (PF) was immediately evident in a
moribund 2.7 kg newborn girl delivered by emergency
caesarean section for fetal tachycardia (200/minute by
cardiotocography) at 35 week gestation 1. There was no
family history of bleeding disorder. The membranes were
ruptured 3 hours prior to delivery. The mother developed
intrapartum fever (38.9°C) with chills and rigors and was
given intravenous ampicillin and gentamicin 23 minutes
before delivery by emergency caesarean section. At birth,
the baby was apneic with heart rate of 80/minute. She
cried and the heart rate responded upon bag and mask
ventilation for 1 minute. Apgars were 8 and 10 at 1 and 5
minutes, respectively. On arrival at the NICU, the baby
developed further apneas with cyanosis followed by tach-
ypnea, insucking chest and grunting. Her mean arterial
blood pressure was 30 mmHg and heart rate 190/minute.
Arterial blood gas analysis showed a pH of 7.19, pCO2
8.03 kPa, pO2 2.25 kPa, and base excess of -6.9 mmol/L.
Respiratory support (nasal continuous positive airway
pressure of 5 cm H2O with 8 L/min of oxygen), normal
saline bolus, and intravenous penicillin plus gentamicin
were administered within the first hour of resuscitation.
In the next 2 hours, she remained hypotensive despite fur-
ther saline boluses, dopamine infusion and mechanical
ventilation. Group B streptococcus, sensitive to penicillin,
was isolated from the blood cultures of the mother and
the infant. She was aggressively treated with broad antibi-
otic coverage, cardiopulmonary support with mechanical
ventilation and multiple inotropes, and peritoneal dialy-
sis (Table 1). The purpuric rash became more extensive
and she developed progressive multi-organ system failure
despite full intensive care support and succumbed 9 days
later
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Discussion
This report illustrates that PF is an ominous cutaneous
sign of fulminant neonatal GBS septicemia. Childhood PF
is often associated with meningococcaemia [1-3]. In the
neonatal period group B streptococcus is the major cause
of PF but gram negative organisms such as Escherichia coli
and Enterobacter have been described [7-11].
Nolan et al reported two cases of PF associated with
meningococcal and chickenpox, respectively, and
reviewed various treatment modalities [1]. Protein C and
antithrombin III have been given if these factors are defi-
cient [1,5]. In PF associated with meningococcemia and
septic shock, Rivard et al described severe acquired pro-
tein C deficiency successfully treated with conventional
therapy and high-volume plasma exchange as a source of
protein C [2]. Many other therapies have been described
in case reports that claimed to arrest the progression of
neonatal PF, such as the use of heparin [8], Protein C
[5,12], Antithrombin III, recombinant tissue plasmino-
gen activator (rtPA), epoprostenol (prostacyclin) [6], top-
ical nitroglycerin, intravenous dextran, and
plasmapheresis [1-13]. Nevertheless, there is no strong
evidence in favor of one particular therapy due to the
small number of cases.
One limitation of our case was that the coagulopathy was
immediately treated empirically before the endogenous
activities of the anticoagulant factors protein C, protein S,
and Antithrombin III (AT III) were assessed. In case any of
these factors are found to be affected, human protein C or
recombinant human activated protein C may be consid-
Purupura fulminans (PF) Figure 1
Purupura fulminans (PF) was immediately evident in a 
moribund 2.7 kg newborn girl delivered by emergency cae-
sarean section for fetal tachycardia (200/minute by cardioto-
cography) at 35 week gestation.
Table 1: Multi-organ system failure in the neonate with group B streptococcal septicemia
Organ system Abnormal findings Management
Cardiovascular Cardiogenic and distributive shock; poor perfusion; 
ejection fraction 54% and fractional shortening 26%
. Highest creatine phosphokinase 1033 U/l and cardiac 
troponin 0.45 ug/l
Intravenous saline boluses, dopamine, dobutamine, epinephrine, 
hydrocortisone, milrinone, vasopressin
Respiratory Respiratory failure with hypercarbnia and diffuse 
haziness on chest radiograph
Mechanical ventilation, FiO2 1.0, surfactant, vecuronium
Renal Passed urine at 10 hours of life; persistent oliguria; 
anuria 4 days later. Highest creatinine 153 umol/l
Intravenous frusemide; peritoneal dialysis; gentamicin stopped
Septicemic Group B streptococcus, sensitive to penicillin, isolated 
on surface swabs, and in baby and mother's blood 
cultures; highest C-reactive protein 12.9 mg/l
Intravenous penicillin and gentamicin initially; ampicillin; cefotaxime; 
meropenim and vancomycin empirically; intravenous immunoglobulin
Subsequently on high-dose penicillin and cefotaxime when group B 
streptococcus and sensitivity were available.
Hematologic Disseminated intravascular coagulopathy with lowest 
hemoglobin 8.6 g/dl, thrombocytopenia 13 × 109/l, D-
dimer 9735 ng/ml, prothrombin time 60 seconds, and 
activated plasma thromboplastin time 120 seconds
Packed red cell, fresh frozen plasma, cryoprecipitate, platelet
Metabolic Metabolic acidosis (worst pH 6.87), hypoglycemia 
(glucose 1.0 mmol/l), hypocalcemia (0.63 mmol/l)
Dextrose and NaHCO3 infusion; calcium supplementation
Neurologic Convulsion Anticonvulsant
Hepatic Deranged liver function with worst total bilirubin of 125 
umol/l and alanine aminotransferase 574 IU/l
Supportive and treating underlying infectionPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Italian Journal of Pediatrics 2009, 35:10 http://www.ijponline.net/content/35/1/10
Page 3 of 3
(page number not for citation purposes)
ered, and protein C, protein S, and AT III genes should
have been analyzed in the patient and her parents. There
was no family history of coagulopathy and group B strep-
tococcus was identified to be the pathogen, making syn-
dromes of congenital anticoagulant factor deficiency
unlikely in this patient.
Regardless of the pathogen, neonatal PF must be
promptly recognized and aggressively treated in children
[1-6]. Early goal-directed therapy provides significant ben-
efits with respect to outcome in adult patients with severe
sepsis and septic shock [14]. The therapy involves adjust-
ments of cardiac preload, afterload, and contractility to
balance oxygen delivery with oxygen demand. Guidelines
were proposed through the Surviving Sepsis Campaign to
improve outcome in septic patients [15]. They are difficult
to apply routinely and validate in neonates. As Claessens
et al has commented, attempts to apply all of the proce-
dures recommended by the experts, despite the apparent
pragmatism of those procedures, have varied widely; diag-
nosis may be problematic because of atypical or unspe-
cific presentations, biomarkers are of little help at the start
of treatment and are unspecific, supportive treatment
often depends on local supply of resources, and specific
devices are often absent for initial therapy and monitoring
[15]. Resuscitation policy for septic shock in neonates
generally includes prompt treatment of the underlying
infection with broad spectrum antibiotics, replacement of
fluids or blood for preload, appropriate usage of ino-
tropes for cardiac contractility and afterload, support of
oxygenation and ventilation with mechanical ventilation,
and support of individual multi-organ system failure [16].
Despite full intensive care support, PF is often associated
with multiple organ failure and high mortality in children
[4]. PF has a reported mortality of 50 per cent secondary
to multiple organ failure which commonly accompanies
the syndrome and is associated with major long-term
morbidity in those who survive [4]. In 3 cases of early neo-
natal PF, all the babies survived but had markedly com-
promised neurologic outcomes [7].
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